Hosted on MSN2mon
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals
The QWINT-1 study compared efsitora to daily injections of Sanofi’s SNY Lantus (insulin glargine) for 52 weeks in T2D patients using basal insulin for the first time. The QWINT-3 study compared ...
pharmaphorum7d
FDA rejects Novo Nordisk’s weekly basal insulin
Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US. The FDA sent the Danish ...
Knowridge14d
New diabetes drugs may lower heart disease risks, study finds
The rise in type 2 diabetes has become a significant public health concern in recent years. This form of diabetes happens ...
Hosted on MSN8mon
EMA CHMP recommends Novo Nordisk’s weekly insulin for diabetes
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Novo Nordisk's Awiqli, a once-weekly basal insulin icodec, for ...
pharmaphorum4d
Novo Nordisk once-weekly insulin clears first phase 3 test
Novo Nordisk said that if approved for use, insulin icodec would reduce the number of basal insulin injections needed per year for type 2 diabetics from 365 to 52, a significant reduction in ...
Medscape4d
The Glucagonostatic and Insulinotropic Effects of Glucagon-like Peptide 1 Contribute Equally to its Glucose-lowering Action
On days 2–5, pancreatic endocrine clamps were performed using somatostatin infusions of somatostatin and/or selective replacement of insulin and glucagon; day 2, GLP-1 plus basal insulin and ...
Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study
Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery - Observed weight loss was 17% at 28 days, a 25% ...